Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

PURPOSE: The independent predictive information from progesterone receptor (PgR) positivity for breast cancer treated with tamoxifen has been questioned after an overview by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). However, the studies in the overview were to a large content...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordenskjöld, Anna, Fohlin, Helena, Fornander, Tommy, Löfdahl, Britta, Skoog, Lambert, Stål, Olle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065613/
https://www.ncbi.nlm.nih.gov/pubmed/27722840
http://dx.doi.org/10.1007/s10549-016-4007-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065613/
https://www.ncbi.nlm.nih.gov/pubmed/27722840
http://dx.doi.org/10.1007/s10549-016-4007-5

Ejemplares similares